EMEA-002252-PIP01-17

Key facts

Active substance
T-cell bispecific antibody targeting carcinoembryonic antigen expressed on tumor cells and CD3 epsilon chain present on T-cells
Therapeutic area
Oncology
Decision number
P/0091/2018
PIP number
EMEA-002252-PIP01-17
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
Route(s) of administration
Intravenous use
Contact for public enquiries
Roche Registration Limited
Tel. +41 616879411
E-mail: global.paediatrics@roche.com
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating